Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates. We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib worldwide.
M ultiple myeloma (MM) is a clonal plasma cell neoplasm with substantial morbidity and mortality, characterized by end organ damage-renal impairment, hypercalcemia, lytic bony lesions, and anemia. With the development of better therapies, myeloma has changed from an untreatable ailment to one that is still not curable but treatable with mostly outpatient therapy. Myeloma treatment has improved substantially over the past decade. The first major advance was the development of autologous stem cell transplant (ASCT) in the 1980s and 1990s. 1 So-called novel agents were first developed in the late 1990s and early 2000s-beginning with the "IMIDs" (thalidomide and lenalidomide) and followed by the proteasome inhibitors (PIs). 2 More recently, monoclonal antibodies, such as daratumumab and elotuzumab, and histone deacetylating agents, such as panobinostat, have also been approved by the US Food and Drug Administration (FDA). 2 Myeloma is unique as a cancer because basic diagnostic testing includes only a complete blood cell count with differential, basic metabolic panel; serum calcium, serum and urine protein electrophoresis; and osseous survey, all of which should be accessible in low-and middle-income countries (LMICs). 3, 4 Many advanced tests, such as the serum-free light-chain assay, fluorodeoxyglucose-positron emission tomography (FDG PET) scan, cytogenetics, and fluorescence in situ hybridization (FISH) may not be available. Because of this, resourcestratified guidelines for the diagnosis and treatment of MM have been developed. 4 Another unique feature of myeloma is that treatment can be delivered almost exclusively in the outpatient setting (with the exception of ASCT).
Standard treatment for myeloma is largely dependent on patient fitness and underlying health status. For those in good health and younger than 70 to 75 years, the preferred treatment for newly diagnosed patients with myeloma comprises a triplet novel agent regimen, typically including an IMID and PI in combination with glucocorticoids, followed by ASCT and maintenance therapy with low-dose IMID or PI. 5, 6 For those unable to undergo ASCT, standard therapy includes induction with novel agents and low-dose maintenance therapy. 7 Despite improvements in the care of patients with myeloma, these advances have largely delivered better outcomes to patients in high-income countries. In many LMICs, delivery of cancer care is often hindered by lack of access to general and specialized health care, diagnostics, and advanced treatments, like novel agents, radiation oncology, and stem cell transplantation, leading to poor outcomes. In studies of patients with myeloma treated in Nigeria, lack of access to affordable health care, late presentation, and inadequate treatment were suggested as common factors contributing to poor outcomes, with a 5-year survival of only 7.6%. 8, 9 Necessary data to inform health policies with respect to myeloma on a global level, including cancer control and implementation plans, are not widely available. These include data on incidence, mortality, and availability of effective therapies such as IMIDs, PIs, and ASCT. This study therefore aims to describe the global burden of myeloma from 1990 to 2016 by age, sex, and sociodemographic index (SDI) (a summary indicator of income per capita, educational attainment, and fertility) and to describe the availability and/or approval of effective therapies, such as PIs, IMIDs, and ASCT, worldwide. Understanding these factors for myeloma is critical to establish the need for diagnosis and treatment and to demonstrate differences in myeloma incidence, which can foster further research on the underlying etiologies for myeloma.
Methods
Flowcharts describing the process to estimate mortality, incidence, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) can be found in eFigures 1 and 2 in the Supplement. Methods for the Global Burden of Disease (GBD) study and the cancer estimation have been described in detail previously. 3,10-12 To estimate myeloma mortality, we used vital registration (VR) system as well as cancer registry (CR) data. Data sources used for myeloma mortality can be found in the GBD source tool (http://ghdx.healthdata .org/gbd-2016/data-input-sources). The VR and CR data were processed in multiple steps. Major adjustments included the redistribution of undefined codes ("garbage codes") or codes that cannot be considered to refer to underlying causes of death, and mapping of different coding systems to GBD causes. 13 Codes from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) mapped to the GBD cause "multiple myeloma" were C88 ("malignant immunoproliferative diseases and certain other B-cell lymphomas") and C90 ("multiple myeloma and malignant plasma cell neoplasms"). Cancer registry incidence data were transformed to mortality estimates by using separately modeled mortality-to-incidence ratios (MIRs). The VR data were combined with the mortality estimates that were derived from CR MM incidence data and used as input for an ensemble model of mixed-effects linear models and spatiotemporal Gaussian process regression models for MM cause fractions and death rates. 14 Covariates used in the models can be found in the Appendix (eTable 1 in the Supplement). Myeloma mortality was adjusted to fit into the separately estimated all-cause mortality in a process called "CodCorrect," which is an algorithm that scales single causes of death to all-cause mortality and child causes to parent causes. 10 The YLLs were estimated by calculating the difference between a standard life expectancy and the age at death. 13 Final MM mortality estimates were divided by MIR, resulting in incidence estimates.
Myeloma survival was estimated by scaling GBD locations between a theoretical best-case and worst-case scenario using the MIR as a scaling factor. For each incidence cohort, 10-year prevalence was estimated using the modeled survival. Ten-year myeloma prevalence was divided into 4 sequelae: (1) diagnosis and treatment (7 months), 15 (2) remission (remaining duration after taking into account the other sequelae), (3) metastatic and/or disseminated phase (37 months), 16 and (4) terminal phase (1 month). Each sequela prevalence was multiplied with a distinct disability weight, which can be found in eTable 2 in the Supplement, and these were summed to generate YLDs. 13 DALYs were calculated as the sum of YLDs and YLLs. 11 Rates are reported per 100 000 person-years with a 95% uncertainty interval (UI) reported in parentheses. For the age standardization, the GBD world population standard was used. 17 For measuring availability of effective therapies, lenalidomide global approval information as of 2016 was provided by the Australian Therapeutic Goods Administration. 18 Bortezomib global approval was determined via personal communication with Takeda Oncology (email communication; Takeda Oncology; May 3, 2018). Data on stem cell transplant availability were reported using a prior publication by the World Bone Marrow Transplant Society. 19 To estimate the effect of population growth on myeloma incidence, we applied the population size of 2016 onto the rate, sex, and age structure of 1990. To estimate the effect of aging on incident cases, we applied the age structure of 2016 onto the rate, sex distribution, and population size of 1990. To estimate the effect of changing age-specific incidence rates on the incident cases, we applied the incidence rates for 1990 onto the population size and age structure of 2016.
Results
Data used for the MM estimates included 16 005 site-years from a vital registration system and 2737 site-years from cancer registry data. In 2016 there were 138 509 (95% UI, 121 000-155 480) incident cases of MM, with an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95% UI, 1.8-2.3). Multiple myeloma was responsible for 98 437 (95% UI, 87 383-109 815) deaths globally with an age-standardized death rate (ASDR) of 1.5 per 100 000 persons (95% UI, 1.3-1.7). Multiple myeloma was responsible for 2.1 million (95% UI, 1.9-2.3 million) DALYs at the global level in 2016, with an age-standardized rate of 30.5 (95% UI, 27.4-33.9) DALYs per 100 000 person-years (eTable 3 in the Supplement). From 1990 to 2016, MM incident cases increased by 126%, and deaths increased by 94% (eTable 4intheSupplement). Among SDI quintiles, the largest increase (192%) was seen in middle SDI countries (from 7974 [95% UI, 7233-8821] in 1990 to 23 273 [95% UI, 21 136-26 947] in 2016). Of the 126% increase in incident cases at the global level, population growth contributed 40.4%, an aging world population contributed 52.9%, and increases in age-specific incidence rates contributed 32.6% (eTable 4 in the Supplement). Among the regions, the largest increase in incident cases from 1990 to 2016 was seen in East Asia (China, North Korea, and Taiwan), with a rise of 262% (from 4760 [95% UI, 4271-5575] in 1990 to 17 218 [95% UI, 14 482-19 093] in 2016). The largest contributor to this increase was a rise in age-specific incidence rates (contributing 157%), followed by an aging population (contributing 85%) and population growth (contributing 20%) (eTable 4 in the Supplement).
The 3 world regions with the highest ASIR of MM were Australasia (5.8; 95% UI, 4.4-6.5), high-income North America (5.2; 95% UI, 4.7-6.5), and Western Europe (4.6; 95% UI, 3.7-5.5) (eTable 3 in the Supplement). The 3 highest ASDR were seen in high-income North America (3.0; 95% UI, 2.6-3.6), Australasia (2.8; 95% UI, 2.1-3.1), and Western Europe (2.6; 95% UI, 2.1-3.1). In terms of absolute numbers, Western Europe was the region with the most cases of myeloma for both sexes in 2016 (35 433; 95% UI, 28 272-42 151), followed by high-income North America (27 003; 95% UI, 24 157-33 637) and East Asia (17 218 . The ASIR and ASDR were the highest in high-income countries with an almost 10-fold difference between countries with the lowest and the highest ASIR and ASDR (Figure 1 ; eFigure 3intheSupplement). From 1990 to 2016, ASIRs rose in all SDI quintiles except for the low SDI quintile, where they remained stable (eFigure 4 in the Supplement). However, AS-DRs peaked in the high-SDI quintile around the year 2000 and have been declining since. The same trend can be seen in highmiddle SDI countries, with a more recent peak in ASDRs around 2005 and declining rates since. ASDRs in the other SDI quintiles have been rising (eFigure 5 in the Supplement). All results presented herein can also be found online at https: //vizhub.healthdata.org/gbd-compare/.
For stem cell transplant availability, the top 5 countries with the highest rates (per 10 million population) of stem cell transplantation (for all indications, not just MM) were Israel (814), Italy (671), Germany (665), Sweden (625), and the Netherlands (614) ( Figure 2) . Some regions of the world lack access to stem cell transplantation entirely, particularly sub-Saharan Africa (with the exception of South Africa). With respect to drug availability, as of 2016, out of 195 countries and territories, lenalidomide (Revlimid) had been approved in 73 countries and bortezomib (Velcade) in 103 countries ( Figure 3) . Notably, neither drug has been approved in most countries in sub-Saharan Africa and some countries in Central Asia.
Discussion
Age-standardized incidence and death rates are highest in the Australasian, North American, and Western European populations. The world regions with the lowest age-standardized incidence of MM are Asia, Oceania, and sub-Saharan Africa. These results are in line with those of prior studies that have shown that the reported incidence for hematologic malignant neoplasms is higher in high-income countries compared with LMIC 20,21 With respect to these differences between incidence of MM in highincome and LMIC, a full discussion of the predisposition for myeloma is beyond the scope of this report, but known risk factors include antecedent diagnosis of monoclonal gammopathy of undetermined significance or smoldering myeloma, and possible occupational risk factors. 22 In addition, there have been recently described autosomal germline mutations that can predispose a patient to MM. 23 At least some of the differences in incidence may be due to lack of diagnostic abilities in lower SDI countries compared with high SDI countries and do not necessarily reflect differences in disease biology (eFigure 6 in the Supplement shows a map of the SDI quintiles). Supporting this hypothesis is the fact that the disease burden of MM in African Americans in the United States is markedly higher than that of European Americans in the United States, yet the disease burden among Africans living in Africa is among the lowest in the world, as shown in our study and in previous studies. 24, 25 To explain the heterogeneity in incidence, collaborative research within the global oncology community is required on 2 fronts: the basic research question of differences in underlying disease biology, and the population health question of underascertainment. Despite the heterogeneous geographical burden of myeloma, time trends show that incident cases of myeloma have increased in all regions and have more than doubled for all SDI quintiles from 1990 to 2016. Global incident cases of myeloma increased by 126%, with aging contributing 52.9%. This is in line with the increase seen for other cancers that predominantly affect an older population. Prostate cancer cases at the global level, for example, increased by 217% from 1990 to 2013. 26 We also showed that among SDI quintiles, the largest increase of 192% in incidence cases was seen in middle-SDI countries with an aging population and rising age-specific rates contributing equally. Among regions, the largest increase of 262% was seen in East Asia, mostly from a rise in age-specific incidence rates. Given the lack of known strong risk factors for myeloma, research in locations with rapidly rising incidence rates might help to identify predisposing factors and guide future preventative strategies.
We have also described an improvement in ASDRs for MM from 1990 to 2016 in high-income SDI regions despite increasing incidence rates, which is likely reflective of improvements in treatments. Novel agents, such as PIs and IMIDs, in addition to high-dose melphalan and ASCT, have changed the therapeutic landscape, with improvement in 5-year survival rates from 25.1% in 1975 to 1979 to 52.7% in 2009 With respect to availability of effective therapies, we described the approval status of bortezomib and lenalidomide and the availability of ASCT as a surrogate measure, although our ability to assess true "availability"-as determined by factors such 
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Global Burden of Multiple Myeloma as cost, affordability, and willingness of insurers or governments to pay for cancer treatments-is limited. Prior research has demonstrated major differences in affordability of important cancer drugs around the world-bortezomib was specifically examined in this analysis. 28 Nonetheless, 2 drugs that are now considered standard of care, lenalidomide and bortezomib, have not been approved in some African and Middle Eastern countries, and it is notable that there are no stem cell transplant centers in sub-Saharan Africa, with the exception of South Africa. Thus, on a global level there are marked discrepancies in the availability of effective therapies. In addition to ensuring universal access to health care, as specified in target 3.8 of the Sustainable Development Goals, it is imperative to at least ensure access to highly effective medications. 29 Initiatives like the market access agreements negotiated by the American Cancer Society and the Clinton Health Access Initiative with Pfizer Inc and Cipla Inc to expand access to essential cancer medications are hopefully reflective of improved affordability, as has been the case with antiretroviral treatments for HIV/AIDS. 30
Limitations
Limitations of our study are that data informing the models to estimate the burden of myeloma are often scarce, especially in LMICs where vital registration systems and cancer registries are lacking or cover only a small part of the population. The uncertainty around our estimates in these locations is therefore large.
Supporting the development of cancer registries and expanding vital registration systems in these areas are crucial. Unfortunately, our attempts to obtain data on drug sales from pharmaceutical companies were unsuccessful, and therefore we could report only drug availability. Given the challenges of estimating access to generic drugs like thalidomide, we chose to report approval rates of lenalidomide and bortezomib with the understanding that thalidomide might represent an effective treatment options in countries that have not approved lenalidomide. Other questions, such as which drugs are available through government-sponsored health plans, which phases of the disease the drug is approved in, which combinations are approved, were not specifically examined, and thus we were limited in making more definitive conclusions about drug "access" beyond regulatory approval. As an important example, within the European Union (EU), the European Medicines Agency (EMA) is responsible for the authorization of medicines in EU countries. The EMA has approved lenalidomide for use in the EU; however, member countries have individually decided whether the drug will be paid for by governmental health insurance. Thus, although marketing approval may be present, it does not guarantee that a drug will be covered by insurances or that patients can afford the cost. With respect to transplantation, we reported prior data analyzing global availability of transplantation but did not have access to myelomaspecific transplant rates. Further research is needed to fully de- scribe details on the availability, access, and reimbursement of effective treatments for myeloma.
Conclusions
Although more common in high SDI countries, myeloma is a global disease, and there has been a marked increase in inci-dent cases from 1990 to 2016, predominantly in middle SDI countries and East Asia. Approval for effective drugs and stem cell transplantation options are lacking in many low-SDI countries. Collaborative global efforts are needed to ensure that every patient with myeloma is being diagnosed and has access to effective treatment. Further research is needed to determine the reasons behind the observed heterogeneity in disease burden. (1743 7.1 (4.5 4.6 (3.2 5.8 (4.2 687 (439 520 (363 1207 3.5 (2.2 2.2 (1.5 2.8 (2.1 to Incidence, prevalence, YLD estimation -multiple myeloma Abbreviations: MIR: mortality to incidence ratio, MM: multiple myeloma, t: time (years), YLD: Years lived with disability eFigure 2: Flowchart describing estimation steps for multiple myeloma incidence, prevalence, and YLDs
